Waters (WAT) Earnings Date & Reports
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools... Show more
WAT is expected to report earnings to rise 11.48% to $3.01 per share on August 04
Waters Corporation (WAT) First Quarter 2026 Earnings Recap: Beats Estimates on Revenue and EPS Surge
Key Takeaways
- Waters Corporation reported Q1 2026 revenue of $1.267 billion, surpassing consensus estimates of about $1.20 billion and the high end of company guidance by $56 million.
- Adjusted EPS came in at $2.70, beating analyst expectations of $2.31 and growing 20% year-over-year from $2.25.
- Organic revenue reached $747 million, up 13% reported and 11% constant currency, driven by strong performance in Analytical Sciences.
- Acquired Biosciences and Diagnostic Solutions businesses contributed $520 million, $40 million above guidance, with 7% pro forma growth.
- Company raised full-year 2026 guidance: organic constant currency growth to 6.5%-8.0%, total revenue $6.405-$6.455 billion, adjusted EPS $14.40-$14.60.
- Shares surged over 12% in response, reflecting investor enthusiasm for integration success and raised outlook.
Earnings Context and Why It Matters
Waters Corporation (NYSE: WAT), a leader in analytical instruments and services for life sciences, materials, food, and environmental applications, released its first quarter 2026 earnings on May 5, 2026, covering the period ended April 4, 2026. This report marked the first full quarter including the Biosciences and Diagnostic Solutions businesses acquired from Becton, Dickinson and Company (BD) on February 9, 2026. The acquisition significantly expanded Waters' portfolio in high-growth areas like flow cytometry and diagnostics, amid a challenging macro environment with China headwinds and softening biopharma spending. Investors watched closely for integration progress, organic growth momentum, and synergy realization, as these signal Waters' ability to leverage its scale for sustained leadership in precision instruments.
Waters delivered standout Q1 2026 results, with total net revenue of $1.267 billion, up 91% from $662 million in Q1 2025 (ended March 29, 2025). This beat consensus revenue estimates of approximately $1.20 billion and exceeded the company's guidance range of $1.198-$1.211 billion. Organic revenue was $747 million, reflecting 13% reported growth and 11% constant currency growth, fueled by 14% growth in the Analytical Sciences Division (instruments up 8%, chemistry up 13%, service up 14%). The acquired businesses added $520 million on an owned-period basis (post-Feb 9), up 7% pro forma versus the prior-year equivalent period, beating internal expectations by $40 million.
GAAP diluted EPS was a loss of $0.87, versus $2.03 profit last year, due to $99 million inventory step-up and $152 million amortization of purchased intangibles from the acquisition. Adjusted non-GAAP EPS of $2.70 rose 20% from $2.25, topping consensus of $2.31 and guidance midpoint of $2.30. Adjusted operating income hit $300 million (23.6% margin), up from prior periods on strong revenue and cost discipline. CEO Udit Batra highlighted "double-digit organic growth in legacy businesses" and early revenue synergies.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization (market cap), technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across diverse portfolios. Explore it today to streamline your research.
Market Reaction and Investor Sentiment
Waters' shares rocketed over 12% on May 5, 2026, following the earnings release before market open, with intraday gains reaching 13.5% and closing around $339—adding billions to market cap. The surge reflected relief over seamless BD integration, organic beats, and upbeat guidance, countering pre-earnings caution around acquisition costs and China exposure. Investor sentiment turned bullish, with analysts noting strong execution and synergy potential as key positives.
Forward Outlook and Key Factors to Monitor
Waters raised its full-year 2026 guidance, projecting organic constant currency revenue growth of 6.5%-8.0% (organic reported revenue $3.370-$3.420 billion), acquired business revenue of $3.035 billion (embedding $35 million synergies), and total revenue of $6.405-$6.455 billion. Adjusted EPS guidance climbed to $14.40-$14.60, implying 10%-11% growth, with adjusted EBIT margin at 28.2% and tax rate of 16.0%. For Q2 (ending circa early July 2026), expect organic constant currency growth of 6.0%-8.0%, total revenue $1.616-$1.631 billion, and adjusted EPS $2.95-$3.05.
Key watch items include BD integration milestones, like $55 million cost synergies from procurement, site rationalization, and organization optimization. Revenue synergies from cross-selling mass spectrometry, service attachment, and e-commerce could accelerate growth in Biosciences (flow cytometry) and Diagnostics (microbiology, molecular diagnostics). Monitor pharma/biopharma demand for instrument replacement and GLP-1 (glucagon-like peptide-1) manufacturing tools, alongside non-pharma segments like batteries and EVs. China recovery, new product launches (e.g., FACSDiscover), and margin expansion from cost actions will shape trajectory amid forex and macro pressures.
Upcoming catalysts: Q2 earnings in late July/early August 2026; progress on at-home testing expansions aligned with U.S. health priorities; free cash flow normalization post-acquisition working capital shifts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
a manufacturer of analytical technologies: liquid chromatography, mass spectrometry, and thermal analysis
Industry MedicalSpecialties